Drug Trial Radar · NCT07365462
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 6, 2026
Primary completion
Feb 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Jan 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
Conditions
- Tardive Dyskinesia
Interventions
NBI-1065890Drug
Oral administration
PlaceboDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 8 Based on the Blinded Central AIMS Video Raters' AssessmentTime frame: Baseline and Week 8
Locations
48 sites in 6 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Bryant, Arkansas · Recruiting
Neurocrine Clinical Site
Chino, California · Recruiting
Neurocrine Clinical Site
Fountain Valley, California · Recruiting
Neurocrine Clinical Site
Huntington Beach, California · Recruiting
Neurocrine Clinical Site
Long Beach, California · Recruiting
Neurocrine Clinical Site
San Diego, California · Recruiting
Neurocrine Clinical Site
Temecula, California · Recruiting
Neurocrine Clinical Site
Torrance, California · Recruiting
Neurocrine Clinical Site
Boca Raton, Florida · Recruiting
Neurocrine Clinical Site
Bonita Springs, Florida · Recruiting
Neurocrine Clinical Site
Hialeah, Florida · Recruiting
Neurocrine Clinical Site
Hialeah, Florida · Recruiting
Neurocrine Clinical Site
Miami, Florida · Recruiting
Neurocrine Clinical Site
Orange City, Florida · Recruiting
Neurocrine Clinical Site
Port Charlotte, Florida · Recruiting
Neurocrine Clinical Site
Tampa, Florida · Recruiting
Neurocrine Clinical Site
Atlanta, Georgia · Recruiting
Neurocrine Clinical Site
Marietta, Georgia · Recruiting
Neurocrine Clinical Site
Naperville, Illinois · Recruiting
Neurocrine Clinical Site
Ann Arbor, Michigan · Recruiting
Neurocrine Clinical Site
Bloomfield Hills, Michigan · Recruiting
Neurocrine Clinical Site
Saint Charles, Missouri · Recruiting
Neurocrine Clinical Site
Lincoln, Nebraska · Recruiting
Neurocrine Clinical Site
Commack, New York · Recruiting
Neurocrine Clinical Site
Charlotte, North Carolina · Recruiting
Neurocrine Clinical Site
Beachwood, Ohio · Recruiting
Neurocrine Clinical Site
Fairlawn, Ohio · Recruiting
Neurocrine Clinical Site
Austin, Texas · Recruiting
Neurocrine Clinical Site
Fort Worth, Texas · Recruiting
Neurocrine Clinical Site
Houston, Texas · Recruiting
Neurocrine Clinical Site
Stafford, Texas · Recruiting
Neurocrine Clinical Site
Cherven Bryag, Bulgaria · Recruiting
Neurocrine Clinical Site
Kardzhali, Bulgaria · Recruiting
Neurocrine Clinical Site
Novi Iskar, Bulgaria · Recruiting
Neurocrine Clinical Site
Plovdiv, Bulgaria · Recruiting
Neurocrine Clinical Site
Plovdiv, Bulgaria · Recruiting
Neurocrine Clinical Site
Sofia, Bulgaria · Recruiting
Neurocrine Clinical Site
Sofia, Bulgaria · Recruiting
Neurocrine Clinical Site
Varna, Bulgaria · Recruiting
Neurocrine Clinical Site
Veliko Tarnovo, Bulgaria · Recruiting
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.